Skip to main content

Table 4 Number (%) of patients reporting worse, no change, or improved outcomes by treatment

From: The multiple sclerosis relapse experience: patient-reported outcomes from the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry

Treatment

Symptom improvement

Effect of treatment on recovery

 

n

Worse

No change

Improved

p-value

n

Worse

No change

Improved

p-value

Observation only

1574

612 (39)

507 (32)

455 (29)

<0.0001

1514

264 (17)

898 (59)

352 (23)

<0.0001

IVMP

1123

363 (32)

192 (17)

568 (51)

<0.0001

1122

145 (13)

190 (17)

787 (70)

<0.0001

Oral corticosteroids

895

301 (34)

177 (20)

417 (47)

<0.0001

894

116 (13)

224 (25)

554 (62)

<0.0001

Other

745

237 (32)

160 (21)

348 (47)

0.0005

740

114 (15)

196 (26)

430 (58)

<0.0001

  1. IVMP, intravenous methylprednisolone.
  2. Oral corticosteroids include oral methylprednisolone, oral dexamethasone, and oral prednisone. Other includes intramuscular adrenocorticotropic hormone, intravenous immunoglobulin, plasmapheresis, and other responses.
  3. p-values are for effect of treatment on outcome from Pearson’s chi-square test; specifically, the p-value for each row compares that row to the distribution in all subjects not in that row.